Johnson & Johnson

Latest Johnson & Johnson Items
  • This Oct. 16 2012 photo shows Johnson and Johnson products, including Band Aid brand adhesive bandages, arranged for a photo in St. Petersburg, Fla. Johnson & Johnson reports quarterly financial results before the market opens on Tuesday, April 15, 2014. (AP Photo/Chris O'Meara)

    J&J Q1 net up 8 percent on sales jump, lower costs

    A turnaround in Johnson & Johnson's prescription medicine business fueled by new drugs, combined with reduced production and administration expenses, lifted first-quarter profit by 8 percent.


  • Arkansas AG asks court to reconsider drug ruling

    Arkansas Attorney General Dustin McDaniel asked the state Supreme Court on Monday to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson, saying justices did "significant harm" to the state and broke from 170 years of precedent.


  • Arkansas to ask court to reconsider drug fine

    Arkansas Attorney General Dustin McDaniel said Thursday he plans to ask the state Supreme Court to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson over the marketing of the antipsychotic drug Risperdal.


  • FILE - In this Tuesday, July 30, 2013, file photo, large banners hang in an atrium at the headquarters of Johnson & Johnson in New Brunswick, N.J.  Johnson & Johnson has accepted an offer of about $4 billion from the private equity firm The Carlyle Group to buy its Ortho-Clinical Diagnostics business the company said Monday, March 31, 2014, that the deal for the blood-testing unit should close by mid-year. (AP Photo/Mel Evans, File)

    J&J accepts $4B Carlyle offer for diagnostics unit

    Johnson & Johnson has accepted an offer of about $4 billion from the private equity firm The Carlyle Group to buy its Ortho-Clinical Diagnostics business.


  • FILE - This July 2009 file photo shows the sign outside Baxter International Inc. in Deerfield, Ill. Baxter International Inc. on Thursday, March 27, 2014 announced it is splitting itself into two separate businesses _ one focusing on biopharmaceuticals and the other on other medical products. (AP Photo/Arlington Heights Daily Herald, George LeClaire, File) MANDATORY CREDIT; MAGS OUT

    Baxter splitting into 2 separate businesses

    Following a rival's lead, Baxter International Inc. said it's planning a breakup into two health care companies as it tries to boost innovation and profitability and reward shareholders.


  • Women: J&J trashed records in product injury suits

    Lawyers and advocates for women alleging Johnson & Johnson products injured them urged the U.S. Justice Department on Wednesday to investigate their claims the health care giant deliberately destroyed many documents critical to their lawsuits.


  • FILE - In this file photo taken Nov. 19, 2013, Arkansas Attorney General Dustin McDaniel speaks at a Little Rock, Ark., news conference. The Arkansas Supreme Court on Thursday, March 20, 2014, overturned a $1.2 billion judgment against Johnson & Johnson in a lawsuit challenging the drugmaker's marketing of an antipsychotic drug. (AP Photo/Danny Johnston, File)

    Arkansas court tosses $1.2B judgment against J&J

    The Arkansas Supreme Court tossed out a $1.2 billion judgment against Johnson & Johnson on Thursday, reversing a lower court verdict that found the drug maker engaged in fraudulent tactics when marketing the antipsychotic drug Risperdal.


  • Medical groups question price of new hep C drug

    An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences Inc.


  • Montana Attorney General Tim Fox announces a $5.9 million legal settlement with subsidiaries of Johnson & Johnson in Helena, Mont., on Thursday, March 6, 2014. The state's lawsuit claimed Janssen Ortho LLC and Janssen Pharmaceuticals hid the dangers of the antipsychotic drug Risperdal and promoted it for uses not approved by the Food and Drug Administration. (AP Photo/Matt Volz)

    Drug firms settle with Montana for $5.9M

    Subsidiaries of Johnson & Johnson have agreed to pay $5.9 million to settle a lawsuit with Montana over how an anti-psychotic drug was marketed, state Attorney General Tim Fox said Thursday.


Happening Now